Topical therapy for atopic dermatitis. A practical option? Are expectations met?

Marsella, R.; Friberg, Cecilia

doi:10.1002/9781119278368.ch7.7

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of CAD follows a multimodal approach and the treatment strategy required for CAD combines topical and systemic therapies, which need to be tailored to each individual dog and owner situation [ 1 , 2 , 5 ]. Several options are available when it comes to topical therapy, including shampoos, foaming mousses, sprays, wipes, spot-on treatments, creams, and ointments [ 1 , 6 ] but, unfortunately, the currently existing therapies are not always totally effective, and might have some associated adverse effects [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Sphingomyelin-Rich Lipid Extract Collar for Canine Atopic Dermatitis

Segarra,

Sanmiguel,

Zuriaga

et al. 2023

Veterinary Sciences

View full text Add to dashboard Cite

The management of canine atopic dermatitis (CAD) is complex, and it needs to be multimodal, combining topical and systemic therapies. Given that the currently available options are not always totally effective and might have some associated adverse effects, novel alternatives are needed. For this reason, a new collar for CAD was developed with 2.5% of a sphingomyelin-rich lipid extract (LE) with proven benefits for skin health. The release of the active ingredient when incorporated into the collar was tested in vitro, showing an adequate kinetic profile. Then, the efficacy and safety of the collar were assessed in 12 client-owned dogs with CAD in a pilot study. After eight weeks, the dogs experienced significant clinical improvements on the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, Pruritus Index for Canine Atopic Dermatitis (PCAD) and Pruritus Visual Analogue Scale (PVAS) scores, without any adverse effects. Additionally, further in vitro studies were performed, indicating that this LE collar should be compatible with antiparasitic collars (with deltamethrin or imidacloprid/flumethrin) if worn simultaneously. Given the observed benefits of this LE collar, combining it with other CAD therapies could potentially allow for drug sparing, reduction in adverse effects, enhanced owner compliance, and reduced treatment costs.

show abstract